The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2019.1660772
Abstract: ABSTRACT Introduction: Antimicrobial resistance in Gram-negative pathogens is a significant threat to global health. β-Lactams (BL) are one of the safest and most-prescribed classes of antibiotics on the market today. The acquisition of β-lactamases, especially… read more here.
Keywords: gram; gram negative; treatment; bli combinations ... See more keywords
P-1530. Evaluation of Phenotypic Cross-Resistance between Cefiderocol and β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US Medical Centers
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.1698
Abstract: Abstract Background Prevalence of multi-drug resistant P. aeruginosa isolates has been increasing with cross-resistance reported among β-lactam/β-lactamase inhibitor (BL/BLI) combinations. This study evaluates cross-resistance between anti-pseudomonal BL/BLI combinations and cefiderocol (CFDC) against various non-susceptible (NS)… read more here.
Keywords: aeruginosa isolates; cross resistance; bli combinations;